NEW YORK, NY--(Marketwire - September 24, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Robert W. Franz Cancer Research Center, a part of the Providence Cancer Center, located in Portland, Oregon, has joined Delcath’s Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company’s Percutaneous Hepatic Perfusion (PHP) System. This pivotal multi-center study for the isolated, high dose delivery of the anti-cancer agent melphalan is led by the National Cancer Institute (NCI). Providence, the tenth center to join this trial, will be able to provide this treatment option to a previously unreached patient population in the Pacific Northwest region of the United States. Delcath’s Phase III study has recently expanded throughout the U.S., and is now enrolling at the following institutions:
